Use of 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice

Meyoung-Kon Kim, Byoung J. Song, Jürgen Seidel, Yunjo Soh, Kyu Shik Jeong, In Sook Kim, Hisataka Kobayashi, Michael V. Green, Jorge A. Carrasquillo, Chang H. Paik

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recent data suggest that inhibitors of ethanol-inducible cytochrome P450 (CYP2E1) can protect the liver from injury caused by various substrates of CYP2E1. In this study, we measured the protective effect of isopropyl-2- (1,3-dithioetane-2-ylidene)-2[N-(4-methylthiazol-2-yl)-carbamoyl]acetate (YH439), a transcriptional inhibitor of CYP2E1, against carbon tetrachloride (CCl4)-induced hepatotoxicity by using various conventional methods anti dynamic scintigraphy with 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin, a recently developed scintigraphic agent. Balb/c mice were pretreated with two doses of YH439 (50 or 150 mg/kg per day) at 48 h and 24 h and one dose of CCl4 (0.25 mL/kg) at 18 h before scintigraphy. The results were compared with 'those of two other groups, one that received CCl4 but not YH439, and the other that received neither (control). Scintigraphic images were acquired continuously at 15-sec intervals for 30 min. Pharmacokinetic parameters, such as peak liver/heart ratio (r(max)), peak liver uptake time (t(max)), and hepatic half-clearance time (HCT), were obtained from time-activity curves derived from regions-of-interest (ROI) over the liver and the heart. Acute administration of CCl4 alone caused centrilobular necrosis and serum transaminase levels to rise more than 5 times higher than those of the control group. Pharmacokinetic parameters also changed significantly from those of the control group. Administration of YH439 prevented centrilobular necrosis and significantly improved pharmacokinetic parameters. This study demonstrates for the first time that hepatobiliary scintigraphy can be used to study in vivo biochemistry of the CYP2E1 inhibitor (YH439) against liver toxicity.

Original languageEnglish
Pages (from-to)561-568
Number of pages8
JournalNuclear Medicine and Biology
Volume25
Issue number6
DOIs
Publication statusPublished - 1998 Aug 1
Externally publishedYes

Fingerprint

Technetium Tc 99m Mertiatide
Enzyme Inhibitors
Radionuclide Imaging
Liver
Cytochrome P-450 CYP2E1
Pharmacokinetics
Necrosis
Control Groups
Carbon Tetrachloride
Transaminases
Biochemistry
Cytochrome P-450 Enzyme System
biocytin
YH 439
Ethanol
Wounds and Injuries
Serum

Keywords

  • Acute hepatitis
  • Cytochrome P450 2E1
  • In vivo imaging
  • Pharmacokinetics
  • YH439

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Use of 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice. / Kim, Meyoung-Kon; Song, Byoung J.; Seidel, Jürgen; Soh, Yunjo; Jeong, Kyu Shik; Kim, In Sook; Kobayashi, Hisataka; Green, Michael V.; Carrasquillo, Jorge A.; Paik, Chang H.

In: Nuclear Medicine and Biology, Vol. 25, No. 6, 01.08.1998, p. 561-568.

Research output: Contribution to journalArticle

Kim, Meyoung-Kon ; Song, Byoung J. ; Seidel, Jürgen ; Soh, Yunjo ; Jeong, Kyu Shik ; Kim, In Sook ; Kobayashi, Hisataka ; Green, Michael V. ; Carrasquillo, Jorge A. ; Paik, Chang H. / Use of 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice. In: Nuclear Medicine and Biology. 1998 ; Vol. 25, No. 6. pp. 561-568.
@article{0298861049b6427d862fc6b64af73cb0,
title = "Use of 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice",
abstract = "Recent data suggest that inhibitors of ethanol-inducible cytochrome P450 (CYP2E1) can protect the liver from injury caused by various substrates of CYP2E1. In this study, we measured the protective effect of isopropyl-2- (1,3-dithioetane-2-ylidene)-2[N-(4-methylthiazol-2-yl)-carbamoyl]acetate (YH439), a transcriptional inhibitor of CYP2E1, against carbon tetrachloride (CCl4)-induced hepatotoxicity by using various conventional methods anti dynamic scintigraphy with 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin, a recently developed scintigraphic agent. Balb/c mice were pretreated with two doses of YH439 (50 or 150 mg/kg per day) at 48 h and 24 h and one dose of CCl4 (0.25 mL/kg) at 18 h before scintigraphy. The results were compared with 'those of two other groups, one that received CCl4 but not YH439, and the other that received neither (control). Scintigraphic images were acquired continuously at 15-sec intervals for 30 min. Pharmacokinetic parameters, such as peak liver/heart ratio (r(max)), peak liver uptake time (t(max)), and hepatic half-clearance time (HCT), were obtained from time-activity curves derived from regions-of-interest (ROI) over the liver and the heart. Acute administration of CCl4 alone caused centrilobular necrosis and serum transaminase levels to rise more than 5 times higher than those of the control group. Pharmacokinetic parameters also changed significantly from those of the control group. Administration of YH439 prevented centrilobular necrosis and significantly improved pharmacokinetic parameters. This study demonstrates for the first time that hepatobiliary scintigraphy can be used to study in vivo biochemistry of the CYP2E1 inhibitor (YH439) against liver toxicity.",
keywords = "Acute hepatitis, Cytochrome P450 2E1, In vivo imaging, Pharmacokinetics, YH439",
author = "Meyoung-Kon Kim and Song, {Byoung J.} and J{\"u}rgen Seidel and Yunjo Soh and Jeong, {Kyu Shik} and Kim, {In Sook} and Hisataka Kobayashi and Green, {Michael V.} and Carrasquillo, {Jorge A.} and Paik, {Chang H.}",
year = "1998",
month = "8",
day = "1",
doi = "10.1016/S0969-8051(98)00019-5",
language = "English",
volume = "25",
pages = "561--568",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Use of 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice

AU - Kim, Meyoung-Kon

AU - Song, Byoung J.

AU - Seidel, Jürgen

AU - Soh, Yunjo

AU - Jeong, Kyu Shik

AU - Kim, In Sook

AU - Kobayashi, Hisataka

AU - Green, Michael V.

AU - Carrasquillo, Jorge A.

AU - Paik, Chang H.

PY - 1998/8/1

Y1 - 1998/8/1

N2 - Recent data suggest that inhibitors of ethanol-inducible cytochrome P450 (CYP2E1) can protect the liver from injury caused by various substrates of CYP2E1. In this study, we measured the protective effect of isopropyl-2- (1,3-dithioetane-2-ylidene)-2[N-(4-methylthiazol-2-yl)-carbamoyl]acetate (YH439), a transcriptional inhibitor of CYP2E1, against carbon tetrachloride (CCl4)-induced hepatotoxicity by using various conventional methods anti dynamic scintigraphy with 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin, a recently developed scintigraphic agent. Balb/c mice were pretreated with two doses of YH439 (50 or 150 mg/kg per day) at 48 h and 24 h and one dose of CCl4 (0.25 mL/kg) at 18 h before scintigraphy. The results were compared with 'those of two other groups, one that received CCl4 but not YH439, and the other that received neither (control). Scintigraphic images were acquired continuously at 15-sec intervals for 30 min. Pharmacokinetic parameters, such as peak liver/heart ratio (r(max)), peak liver uptake time (t(max)), and hepatic half-clearance time (HCT), were obtained from time-activity curves derived from regions-of-interest (ROI) over the liver and the heart. Acute administration of CCl4 alone caused centrilobular necrosis and serum transaminase levels to rise more than 5 times higher than those of the control group. Pharmacokinetic parameters also changed significantly from those of the control group. Administration of YH439 prevented centrilobular necrosis and significantly improved pharmacokinetic parameters. This study demonstrates for the first time that hepatobiliary scintigraphy can be used to study in vivo biochemistry of the CYP2E1 inhibitor (YH439) against liver toxicity.

AB - Recent data suggest that inhibitors of ethanol-inducible cytochrome P450 (CYP2E1) can protect the liver from injury caused by various substrates of CYP2E1. In this study, we measured the protective effect of isopropyl-2- (1,3-dithioetane-2-ylidene)-2[N-(4-methylthiazol-2-yl)-carbamoyl]acetate (YH439), a transcriptional inhibitor of CYP2E1, against carbon tetrachloride (CCl4)-induced hepatotoxicity by using various conventional methods anti dynamic scintigraphy with 99mTc-mercaptoacetyltriglycine (MAG3)-biocytin, a recently developed scintigraphic agent. Balb/c mice were pretreated with two doses of YH439 (50 or 150 mg/kg per day) at 48 h and 24 h and one dose of CCl4 (0.25 mL/kg) at 18 h before scintigraphy. The results were compared with 'those of two other groups, one that received CCl4 but not YH439, and the other that received neither (control). Scintigraphic images were acquired continuously at 15-sec intervals for 30 min. Pharmacokinetic parameters, such as peak liver/heart ratio (r(max)), peak liver uptake time (t(max)), and hepatic half-clearance time (HCT), were obtained from time-activity curves derived from regions-of-interest (ROI) over the liver and the heart. Acute administration of CCl4 alone caused centrilobular necrosis and serum transaminase levels to rise more than 5 times higher than those of the control group. Pharmacokinetic parameters also changed significantly from those of the control group. Administration of YH439 prevented centrilobular necrosis and significantly improved pharmacokinetic parameters. This study demonstrates for the first time that hepatobiliary scintigraphy can be used to study in vivo biochemistry of the CYP2E1 inhibitor (YH439) against liver toxicity.

KW - Acute hepatitis

KW - Cytochrome P450 2E1

KW - In vivo imaging

KW - Pharmacokinetics

KW - YH439

UR - http://www.scopus.com/inward/record.url?scp=0031595064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031595064&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(98)00019-5

DO - 10.1016/S0969-8051(98)00019-5

M3 - Article

VL - 25

SP - 561

EP - 568

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 6

ER -